Search - tctmd.com

Displaying 461 - 480 of 525

Sort: Relevancy | Date

News Daily News

PRODIGY Published: No Advantage to Long-term Clopidogrel

April 03, 2012

News Industry News

Data Presented at ACC.12 Demonstrate that OrbusNeich’s Genous™ Stent is Feasible and Safe in STEMI Patients

March 27, 2012

News Daily News

La Evaluación de la FFR Contra la Enfermedad de los Vasos Pequeños Mejora los Resultados

L.A. McKeown

March 23, 2012

News Daily News

FFR Assessment for Small Vessel Disease Improves Outcomes

L.A. McKeown

March 23, 2012

News Daily News

OCT Shows Modest Ability to Identify Hemodynamically Severe Lesions

L.A. McKeown

March 15, 2012

News Daily News

La OCT Revela una Cierta Capacidad para Identificar Lesiones Severas a Nivel Hemodinámico

L.A. McKeown

March 15, 2012

News Daily News

SES Effective for Both Focal, Diffuse DES Restenosis

March 13, 2012

News Daily News

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

March 13, 2012

News Daily News

TCTMD’s Top 10 Most Popular News Stories From 2011

Jason Kahn

March 08, 2012

News Daily News

Los 10 Artículos Más Populares de TCTMD de 2011

Jason Kahn

March 08, 2012

News Daily News

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

Yael L. Maxwell

February 15, 2012

News Daily News

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

January 24, 2012

News Daily News

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

Jason Kahn

January 08, 2012

News Conference News

Adenosine-Free Pressure Measurement Found Equivalent to FFR

L.A. McKeown

December 01, 2011

News Daily News

Some New-Generation Stents Prone to Longitudinal Distortion

November 29, 2011

News Industry News

Boston Scientific Receives FDA Approval for PROMUS Element™ Plus Platinum Chromium Stent System

November 21, 2011

News Conference News

Paclitaxel-Eluting Bioabsorbable Stent Shows Advantage over Bare-Metal Version

November 20, 2011

News Industry News

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

November 13, 2011

News Industry News

Elixir Medical Announces DESolve Nx International Pivotal Trial Initiation for Fully Bioresorbable Coronary Scaffold System

November 10, 2011

News Industry News

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

November 09, 2011

Advertisement

PRODIGY Published: No Advantage to Long-term Clopidogrel

Data Presented at ACC.12 Demonstrate that OrbusNeich’s Genous™ Stent is Feasible and Safe in STEMI Patients

La Evaluación de la FFR Contra la Enfermedad de los Vasos Pequeños Mejora los Resultados

FFR Assessment for Small Vessel Disease Improves Outcomes

OCT Shows Modest Ability to Identify Hemodynamically Severe Lesions

La OCT Revela una Cierta Capacidad para Identificar Lesiones Severas a Nivel Hemodinámico

SES Effective for Both Focal, Diffuse DES Restenosis

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

TCTMD’s Top 10 Most Popular News Stories From 2011

Los 10 Artículos Más Populares de TCTMD de 2011

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

Adenosine-Free Pressure Measurement Found Equivalent to FFR

Some New-Generation Stents Prone to Longitudinal Distortion

Boston Scientific Receives FDA Approval for PROMUS Element™ Plus Platinum Chromium Stent System

Paclitaxel-Eluting Bioabsorbable Stent Shows Advantage over Bare-Metal Version

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

Elixir Medical Announces DESolve Nx International Pivotal Trial Initiation for Fully Bioresorbable Coronary Scaffold System

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content